search
Back to results

Active tDCS Versus Sham tDCS for Upper Limb Recovery in Incomplete Tetraplegic Patients

Primary Purpose

Spinal Cord Injury Cervical

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Active tDCS
Sham tDCS
Sponsored by
Montecatone Rehabilitation Institute S.p.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Cord Injury Cervical focused on measuring Neuromodulation, Transcranial Direct Current Stimulation, tDCS, Upper limb, Functional recovery, Early rehabilitation, Incomplete tetraplegia

Eligibility Criteria

18 Years - 74 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Traumatic SCI;
  • SCI neurological level, according to the American Spinal Injury Association (ASIA) definitions, from C3 to C7, included;
  • incomplete SCI (i.e. ASIA Impairment Scale: B, C or D);
  • distance from the SCI event: from 3 to 6 months;
  • residual motor ability of the target upper limb;
  • stable clinical conditions;
  • tolerance to sitting position for at least 45 minutes;
  • subjects capable and collaborating, able to give informed consent in person.

Exclusion Criteria:

  • presence of implanted devices (e.g. pacemakers, intrathecal infusers, neurostimulators, hearing aids);
  • positive history of brain lesions;
  • presence of cerebral metallic implants (clips) or intracranial implants (e.g. ventriculoperitoneal shunt);
  • history of epilepsy or previous state of epileptic disease;
  • mechanical ventilation in place;
  • history of psychotic disorders;
  • history of severe neurodegenerative disease;
  • concomitant pre-existing clinical conditions that may interfere with movements of the target arm or hand (e.g. severe osteoarthritis, joint injuries, plexus injuries, peripheral nerve injuries, partial amputations);
  • use of antiepileptic drugs blocking Sodium o Calcium channels (e.g. Carbamazepine) or N-Methyl-D-Aspartate receptor antagonists (e.g. Dextromethorphan);
  • history of drugs abuse;
  • further contraindications to the use of TMS for PEMs elicitation (e.g. migraine with aura, permanent head / face tattoos);
  • presence of brain tumor;
  • pregnancy in progress.

Sites / Locations

  • Montecatone Rehabilitation Institute S.p.A.Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Active tDCS (A)

Sham tDCS (S)

Arm Description

Two daily tDCS sessions for 5 days a week, for 2 consecutive weeks, are carried out, simultaneously with the usual rehabilitation physiotherapy of the upper limbs. Patients will receive the usual rehabilitation physiotherapy of the upper limbs at least in the 4 weeks before and in the 4 weeks after the tDCS treatment period too.

Two daily tDCS sessions for 5 days a week, for 2 consecutive weeks, are carried out, simultaneously with the usual rehabilitation physiotherapy of the upper limbs. Patients will receive the usual rehabilitation physiotherapy of the upper limbs at least in the 4 weeks before and in the 4 weeks after the tDCS treatment period too.

Outcomes

Primary Outcome Measures

Change in motor function, after the tDCS treatment period completion
Motor function (i.e. muscle strength) of the target upper limb, determined according to the Medical Research Council /International Classification for the Surgery of the Tetraplegic Hand (MRC/ICSTH)

Secondary Outcome Measures

Permanence of motor function, 4 weeks after the tDCS treatment period completion
Motor function (i.e. muscle strength) of the target upper limb, determined according to the Medical Research Council /International Classification for the Surgery of the Tetraplegic Hand (MRC/ICSTH)
Change in strength, sensitivity and grip, up to 4 weeks after the tDCS treatment period completion
Strength, sensitivity and grip of the target upper limb, determined according to the Graded Redefined Assessment of Strength Sensibility and Prehension (GRASSP)
Change in spasticity, up to 4 weeks after the tDCS treatment period completion
Spasticity of the target upper limb, determined according to the Modified Ashworth Scale (MAS)
Change in motor function and muscle activity during rest activity, from the beginning of the tDCS treatment period until 4 weeks after its completion
Motor function and muscle activity during rest activity, determined through Neurographic assessment of the following muscles: deltoid, biceps, carpus extensor, thumb abductor brevis
Change in Motor Evoked Potentials, from the beginning of the tDCS treatment period until 4 weeks after its completion
Motor Evoked Potentials (PEMs), elicited by Transcranial Magnetic Stimulation (TMS), of the following muscles: deltoid, biceps, carpus extensor, thumb abductor brevis
Pain, up to 4 weeks after the tDCS treatment period completion
Pain assessment in the target upper limb, determined according to the Numeric Rating Scale (NRS)
Safety of the tDCS treatment
Incidence of adverse events related to the tDCS treatments
Tolerability of the tDCS treatment
Subjective patient's perception of the fatigue of the treatments with tDCS associated with the usual rehabilitation physiotherapy treatment of the upper limb, evaluated through a short in-house developed questionnaire

Full Information

First Posted
May 20, 2022
Last Updated
June 13, 2023
Sponsor
Montecatone Rehabilitation Institute S.p.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT05390853
Brief Title
Active tDCS Versus Sham tDCS for Upper Limb Recovery in Incomplete Tetraplegic Patients
Official Title
Pilot Randomized Controlled Study on Neuromodulation Through Active tDCS Versus Sham tDCS to Support Upper Limb Motor and Functional Recovery in Sub-acute, Incomplete, Tetraplegic Spinal Cord Injured Patients
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 24, 2023 (Actual)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
November 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Montecatone Rehabilitation Institute S.p.A.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Spinal Cord Injury (SCI) at the cervical level results in motor and sensory impairment below the lesion level and may determine a consistent loss of the use of the upper limbs, with a substantial impact on daily life activities. Therefore, functionality recovery of the upper limbs, of the hands in particular, represents a priority rehabilitation target. Studies in the literature show that the most relevant recovery occurs in the first months after SCI and that neuromodulation techniques may facilitate it. Transcranial Direct Current Stimulation (tDCS ) is a non-invasive neuromodulation technique. The present pilot, randomized controlled study aims at exploring the feasibility and efficacy of an early application of tDCS, in addition to the traditional physiotherapy treatment for the functional recovery of the upper limb, in incomplete traumatic tetraplegic subjects in the sub-acute phase after SCI occurrence. Patients hospitalized at the Montecatone Rehabilitation Institute are randomly assigned to Active tDCS or Sham tDCS.
Detailed Description
Spinal Cord Injury (SCI) at the cervical level results in motor and sensory impairment below the lesion level and may determine a consistent loss of the use of the upper limbs, with a substantial impact on daily life activities. Therefore, functionality recovery of upper limbs, of the hands in particular, represents a priority rehabilitation target. In cases of incomplete tetraplegia, the main rehabilitation goal is the recovery of the maximum functional capacity, in order to improve autonomy or, in the most serious cases, avoid complications due to immobilization. Studies in the literature show that the most relevant recovery occurs in the first months after SCI and that neuromodulation techniques may facilitate it. Transcranial Direct Current Stimulation (tDCS ) is a non-invasive neuromodulation technique capable of modifying cortical excitability through direct, low intensity current, generated by a programmable medical device and delivered through electrodes placed on the scalp. Some authors have explored its potential role in facilitating functional recovery and treating spasticity in SCI subjects, however there are few studies on the use of neuromodulation induced by tDCS as an aid for the functional recovery of upper limbs in tetraplegic subjects. Moreover, most of such studies are on chronic SCI persons only. The present pilot, randomized controlled study aims at exploring the feasibility and efficacy of an early application of tDCS, in the sub-acute phase after SCI occurrence, for the functional recovery of the upper limb, in addition to the traditional physiotherapy treatment, in incomplete traumatic tetraplegic patients, hospitalized at the Montecatone Rehabilitation Institute. They are randomly assigned to Active tDCS (A) or Sham tDCS (S) (parallel arms design,1:1 allocation ratio). Two tDCS daily sessions for 5 days a week, for 2 consecutive weeks, are carried out simultaneously with the usual rehabilitation treatment of the upper limb, that is administered also at least 4 weeks before and 4 weeks after the tDCS treatment period. Most outcomes are measured up to 4 weeks after the completion of the tDCS treatment period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injury Cervical
Keywords
Neuromodulation, Transcranial Direct Current Stimulation, tDCS, Upper limb, Functional recovery, Early rehabilitation, Incomplete tetraplegia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
After selection, enrollment and basal assessments, patients are randomized just before the first tDCS session by the professional who will apply the tDCS and will thus be the only one knowing the assigned intervention during the study
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active tDCS (A)
Arm Type
Experimental
Arm Description
Two daily tDCS sessions for 5 days a week, for 2 consecutive weeks, are carried out, simultaneously with the usual rehabilitation physiotherapy of the upper limbs. Patients will receive the usual rehabilitation physiotherapy of the upper limbs at least in the 4 weeks before and in the 4 weeks after the tDCS treatment period too.
Arm Title
Sham tDCS (S)
Arm Type
Placebo Comparator
Arm Description
Two daily tDCS sessions for 5 days a week, for 2 consecutive weeks, are carried out, simultaneously with the usual rehabilitation physiotherapy of the upper limbs. Patients will receive the usual rehabilitation physiotherapy of the upper limbs at least in the 4 weeks before and in the 4 weeks after the tDCS treatment period too.
Intervention Type
Procedure
Intervention Name(s)
Active tDCS
Intervention Description
tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode. Active stimulation is carried out with a current intensity of 2 milliAmpere. Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes. During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb. In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice.
Intervention Type
Procedure
Intervention Name(s)
Sham tDCS
Intervention Description
tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode. Sham stimulation is carried out through a dedicated program, which increases the current for several seconds up to the target intensity and then decreases it gradually in a few seconds, so that subjects experience the same itching and tingling experience as in active stimulation, but they do not receive any significant therapeutic currents. Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes. During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb. In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice.
Primary Outcome Measure Information:
Title
Change in motor function, after the tDCS treatment period completion
Description
Motor function (i.e. muscle strength) of the target upper limb, determined according to the Medical Research Council /International Classification for the Surgery of the Tetraplegic Hand (MRC/ICSTH)
Time Frame
Baseline 1 (initial visit); Baseline 2 (second visit, 2 weeks after Baseline 1); just before tDCS session n.1 (4 weeks after Baseline 1); just after tDCS session n.20 (6 weeks after Baseline 1)
Secondary Outcome Measure Information:
Title
Permanence of motor function, 4 weeks after the tDCS treatment period completion
Description
Motor function (i.e. muscle strength) of the target upper limb, determined according to the Medical Research Council /International Classification for the Surgery of the Tetraplegic Hand (MRC/ICSTH)
Time Frame
Just after tDCS session n.20 (6 weeks after Baseline 1); 4 weeks after tDCS session n.20 (10 weeks after Baseline 1)
Title
Change in strength, sensitivity and grip, up to 4 weeks after the tDCS treatment period completion
Description
Strength, sensitivity and grip of the target upper limb, determined according to the Graded Redefined Assessment of Strength Sensibility and Prehension (GRASSP)
Time Frame
Baseline 1 (initial visit); Baseline 2 (second visit, 2 weeks after Baseline 1); just before tDCS session n.1 (4 weeks after Baseline 1); just after tDCS session n.20 (6 weeks after Baseline 1); 4 weeks after tDCS session n.20 (10 weeks after Baseline 1)
Title
Change in spasticity, up to 4 weeks after the tDCS treatment period completion
Description
Spasticity of the target upper limb, determined according to the Modified Ashworth Scale (MAS)
Time Frame
Baseline 1 (initial visit); Baseline 2 (second visit, 2 weeks after Baseline 1); just before tDCS session n.1 (4 weeks after Baseline 1); just after tDCS session n.20 (6 weeks after Baseline 1); 4 weeks after tDCS session n.20 (10 weeks after Baseline 1)
Title
Change in motor function and muscle activity during rest activity, from the beginning of the tDCS treatment period until 4 weeks after its completion
Description
Motor function and muscle activity during rest activity, determined through Neurographic assessment of the following muscles: deltoid, biceps, carpus extensor, thumb abductor brevis
Time Frame
just before tDCS session n.1 (4 weeks after Baseline 1); just after tDCS session n.20 (6 weeks after Baseline 1); 4 weeks after tDCS session n.20 (10 weeks after Baseline 1)
Title
Change in Motor Evoked Potentials, from the beginning of the tDCS treatment period until 4 weeks after its completion
Description
Motor Evoked Potentials (PEMs), elicited by Transcranial Magnetic Stimulation (TMS), of the following muscles: deltoid, biceps, carpus extensor, thumb abductor brevis
Time Frame
just before tDCS session n.1 (4 weeks after Baseline 1); just after tDCS session n.20 (6 weeks after Baseline 1); 4 weeks after tDCS session n.20 (10 weeks after Baseline 1)
Title
Pain, up to 4 weeks after the tDCS treatment period completion
Description
Pain assessment in the target upper limb, determined according to the Numeric Rating Scale (NRS)
Time Frame
Baseline 1 (initial visit); Baseline 2 (2 weeks after Baseline 1); just before tDCS session n.1 (4 weeks after Baseline 1); just after tDCS session n.20 (6 weeks after Baseline 1); 4 weeks after tDCS session n.20 (10 weeks after Baseline 1
Title
Safety of the tDCS treatment
Description
Incidence of adverse events related to the tDCS treatments
Time Frame
During and after each tDCS session (from week 4 to week 6 after Baseline 1); in the 4 weeks after tDCS session n.20 (up to 10 weeks after Baseline 1)
Title
Tolerability of the tDCS treatment
Description
Subjective patient's perception of the fatigue of the treatments with tDCS associated with the usual rehabilitation physiotherapy treatment of the upper limb, evaluated through a short in-house developed questionnaire
Time Frame
Just after tDCS session n.20 (week 6 after Baseline 1)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Traumatic SCI; SCI neurological level, according to the American Spinal Injury Association (ASIA) definitions, from C3 to C7, included; incomplete SCI (i.e. ASIA Impairment Scale: B, C or D); distance from the SCI event: from 3 to 6 months; residual motor ability of the target upper limb; stable clinical conditions; tolerance to sitting position for at least 45 minutes; subjects capable and collaborating, able to give informed consent in person. Exclusion Criteria: presence of implanted devices (e.g. pacemakers, intrathecal infusers, neurostimulators, hearing aids); positive history of brain lesions; presence of cerebral metallic implants (clips) or intracranial implants (e.g. ventriculoperitoneal shunt); history of epilepsy or previous state of epileptic disease; mechanical ventilation in place; history of psychotic disorders; history of severe neurodegenerative disease; concomitant pre-existing clinical conditions that may interfere with movements of the target arm or hand (e.g. severe osteoarthritis, joint injuries, plexus injuries, peripheral nerve injuries, partial amputations); use of antiepileptic drugs blocking Sodium o Calcium channels (e.g. Carbamazepine) or N-Methyl-D-Aspartate receptor antagonists (e.g. Dextromethorphan); history of drugs abuse; further contraindications to the use of TMS for PEMs elicitation (e.g. migraine with aura, permanent head / face tattoos); presence of brain tumor; pregnancy in progress.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Silvia Olivi, MD
Phone
+39 0542 632811
Email
silvia.olivi@montecatone.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Silvia Olivi, MD
Organizational Affiliation
Montecatone Rehabilitation Institute S.p.A.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Montecatone Rehabilitation Institute S.p.A.
City
Imola
State/Province
BO
ZIP/Postal Code
40026
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Silvia Olivi, MD
Phone
+39 0542 632811
Email
silvia.olivi@montecatone.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Active tDCS Versus Sham tDCS for Upper Limb Recovery in Incomplete Tetraplegic Patients

We'll reach out to this number within 24 hrs